

Reliable HPLC/UV Quantification of Nitrosamine Impurities in Valsartan and Ranitidine Drug Substances

Margaret Maziarz, Paul D. Rainville

Waters Corporation



This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This application brief demonstrates reliable quantification of six nitrosamine impurities (NDMA, NDEA, NEIPA, NDIPA, NDBA, and NMBA) in valsartan and NDMA in ranitidine by UV detection, with the added benefit of mass confirmation by mass spectral data using an ACQUITY QDa Mass Detector.

Benefits

The ACQUITY Arc System with PDA Detector, integrated with an ACQUITY QDa Mass Detector for accurate mass confirmation, enables reliable quantification of nitrosamine impurities in valsartan and ranitidine drug substances.

Introduction

Carcinogenic impurities, such as nitrosamines, can cause DNA mutations, potentially leading to cancer.¹ Several medications containing valsartan or ranitidine drug substances have been recalled due to the presence of nitrosamine impurities in the final drug products.^{1,2} Due to their high toxicity, these impurities must be monitored at low levels using reliable methods to ensure safety of the pharmaceutical products.

In this work, we present an HPLC method with UV detection for the simultaneous quantification of six nitrosamine impurities in valsartan drug substance, including N-nitrosodimethylamine (NDMA), N-nitroso-N-methyl-4-aminobutyric acid (NMBA), N-nitrosodiethylamine (NDEA), N-nitrosoethylisopropylamine (NEIPA), N-nitrosodiisopropylamine (NDIPA), and N-nitrosodibutylamine (NDBA). This method also enables analysis of NDMA in ranitidine drug substance. The achievable quantitation limits for nitrosamine impurities using UV detection range from 10–20 ng/mL, with method linearity over 10–1000 ng/mL producing $R^2 \geq 0.999$. The mass spectral data from an ACQUITY QDa Mass Detector was used for quick and accurate peak identity confirmation.

Experimental

Table 1. Instrument conditions for analysis of nitrosamine impurities

LC system:	ACQUITY Arc with 2998 PDA and ACQUITY QDa Detectors, passive pre-heater, and flow path 1																															
Column:	XSelect HSS T3 4.6 x 100 mm, 3.5 μm																															
Column temp.:	40 °C																															
Flow rate:	1.0 mL/min																															
Injection volume:	25.0 μL																															
Mobile phase:	A: water with 0.02% of formic acid B: acetonitrile																															
Gradient:	<table><tr><th>Step</th><th>Time (min)</th><th>%A</th><th>%B</th></tr><tr><td>1</td><td>Initial</td><td>95.0</td><td>5.0</td></tr><tr><td>2</td><td>0.50</td><td>95.0</td><td>5.0</td></tr><tr><td>3</td><td>12.00</td><td>5.0</td><td>95.0</td></tr><tr><td>4</td><td>13.00</td><td>5.0</td><td>95.0</td></tr><tr><td>5</td><td>13.10</td><td>95.0</td><td>5.0</td></tr><tr><td>6</td><td>17.00</td><td>95.0</td><td>5.0</td></tr></table>				Step	Time (min)	%A	%B	1	Initial	95.0	5.0	2	0.50	95.0	5.0	3	12.00	5.0	95.0	4	13.00	5.0	95.0	5	13.10	95.0	5.0	6	17.00	95.0	5.0
	Step	Time (min)	%A	%B																												
	1	Initial	95.0	5.0																												
	2	0.50	95.0	5.0																												
	3	12.00	5.0	95.0																												
	4	13.00	5.0	95.0																												
	5	13.10	95.0	5.0																												
6	17.00	95.0	5.0																													
Wash solvents:	Purge: 50:50 water/acetonitrile Sample wash: 80:20 water/methanol Seal wash: 90:10 water/acetonitrile																															
PDA detection:	λ range: 210–400 nm, derived at 245 nm Sampling rate: 10 pts/sec																															
Mass detection:	ACQUITY QDa Ionization mode: ESI+ Acquisition range: 50–500 m/z																															

Results and Discussion

The HPLC separation was performed using an XSelect HSS T3 Column, based on a previously described method.⁴ The conditions of the method were modified to achieve optimal UV performance for nitrosamine impurities in valsartan and ranitidine drug substances. The optimized method (Table 1) provided excellent retention for nitrosamines and separation from the drug substances (Figure 1). While the UV data was used for quantitation, the mass spectral data from an ACQUITY QDa Mass Detector enabled peak identity confirmation by mass detection.




Figure 1. Representative chromatograms of six nitrosamine impurities (1 ug/mL) in valsartan (A) and ranitidine (B) drug substances. UV at 245 nm.

The limit of quantitation (LOQ) for nitrosamine impurities achievable with UV was determined using the signal-to-noise criteria of 10:1. The LOQ solutions were prepared by spiking ~100 µg/mL of drug substance sample in 80:20 water/methanol diluent with the nitrosamines' standards. The LOQ was found to be 10 ng/mL for NDMA, NDEA, and NDIPA, and 20 ng/mL for NMBA, NEIPA, and NDBA, respectively. The LOQ solution at 20 ng/mL of nitrosamines in ~100 µg/mL valsartan is shown in Figure 2. Data from six replicate injections was evaluated to demonstrate performance at the LOQ level (Table 2). The %RSD of the peak areas for six replicate injections of the LOQ solutions was ≤7.51%. The method exhibited a linear response over the 10–1000 ng/mL range with correlation coefficients (R^2) of >0.999 (Table 2). Data was analyzed using Empower 3 Chromatography Data System (CDS) Software.




Figure 2. Limit of quantitation (LOQ) solution with six nitrosamine impurities at 20 ng/mL in valsartan drug substance sample. UV at 245 nm.

Table 2. Limits of quantitation (LOQ) and method linearity for nitrosamine impurities with UV detection, 245 nm.

Impurity	Limit of Quantitation (LOQ)			Method linearity
	LOQ Conc. (ng/mL)	S/N	% RSD of peak areas	R ² (10–1000 ng/mL)
NDMA	10	20	7.51	0.99978
NMBA	20	25	5.25	0.99982
NDEA	10	22	5.32	0.99985
NEIPA	20	24	6.09	0.99987
NDIPA	10	20	8.16	0.99986
NDBA	20	24	5.25	0.99991

Conclusion

A single HPLC/UV method was successfully developed for the reliable quantification of six nitrosamine impurities (NDMA, NMBA, NDEA, NEIPA, NDIPA, and NDBA) in valsartan and NDMA in ranitidine drug substances, with quantitation limits ranging from 10–20 ng/mL. The analysis was performed on the ACQUITY Arc System with 2998 PDA Detector, integrated with an ACQUITY QDa Mass Detector for quick and accurate peak identity confirmation. Additionally, the XSelect HSS T3 Column, a proprietary reversed-phase column, provided retentivity and specificity for all analytes. This HPLC-UV method offers a starting point for the robust quantification of nitrosamines or similar compounds.

References

1. <https://www.uspharmacist.com/article/fda-update-on-recent-voluntary-arb-drug-recalls>
2. <https://www.fda.gov/news-events/press-announcements/statement-alertingpatients-and-health-care-professionals-ndma-found-samples-ranitidine>
3. Maziarz M, Naughton S, Rainville P. Use of a Proprietary Polar Column Chemistry for the Separation of Nitrosamines in Sartan and Ranitidine Drug Substances. Waters Technology Brief. 720006738EN. December 2019.

Featured Products

ACQUITY Arc System <<https://www.waters.com/134844390>>

2998 Photodiode Array (PDA) Detector <<https://www.waters.com/1001362>>

ACQUITY QDa Mass Detector <<https://www.waters.com/134761404>>

720006775, February 2019

©2019 Waters Corporation. All Rights Reserved.